U.S. health regulators have delayed a public meeting to review a COVID-19 vaccine for children under 5.
The agency said it wants to see more data from Pfizer before proceeding.
Friday's extraordinary announcement comes just days before the Food and Drug Administration’s outside experts were set to evaluate the first data on COVID-19 vaccinations in toddlers and babies.
The FDA said it was pushing back the meeting to allow time for Pfizer to provide more data on a three-dose regimen of the vaccine.
(Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.)
The FDA is postponing the Vaccines and Related Biological Products Advisory Committee meeting originally scheduled for Feb. 15. https://t.co/9PeGbQ0dvX pic.twitter.com/MlICu0IQd1
— U.S. FDA (@US_FDA) February 11, 2022
